Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 10, 2023Virtual Press Office and PR Newswire: General Trade show news
Multiplex allogeneic epigenetic edits demonstrate elimination of graft-versus-host disease and resistance of CD8+T, CD4+T, and NK cell responses, while preserving genomic integrity Chroma's...
-
Dec 9, 2023Virtual Press Office and PR Newswire: General Trade show news
Learn more about Servier's leadership in mutant IDH inhibition at ASH booth #1347 BOSTON, Dec. 9, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow...
-
Dec 9, 2023Virtual Press Office and PR Newswire: General Trade show news
-- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM...
-
Dec 9, 2023Virtual Press Office and PR Newswire: General Trade show news
- Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th...
-
Dec 8, 2023Virtual Press Office and PR Newswire: General Trade show news
Open Networking & Edge Summit extends speaking submission deadline to allow extra time for submissions on latest innovation across AI, Cloud Native Networking, and more 2024 industry predictions...
-
Dec 8, 2023Virtual Press Office and PR Newswire: General Trade show news
On December 8, the 2023 Shenzhen Global Investment Promotion Conference was held in Shenzhen, China. Over 380 projects were signed, with a total investment of 1 trillion yuan. The event was...
-
Dec 8, 2023Virtual Press Office and PR Newswire: General Trade show news
From December 5th to 6th, 2023 World Automotive Chip Innovation Conference & 2023 China Automotive Chip Summit was held in Binhu District, Wuxi, E China. The conference focused on cutting-edge...
-
Dec 8, 2023Virtual Press Office and PR Newswire: General Trade show news
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in...
-
Dec 8, 2023Virtual Press Office and PR Newswire: General Trade show news
Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO® (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm New Data Reinforce KYPROLIS® (carfilzomib) as an...
-
Dec 8, 2023Virtual Press Office and PR Newswire: General Trade show news
INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients' blood compared to baseline that was also much larger than a control saline injection A single...